Reading time is 1 mins
.
.
FULL NOTE TO TURKOVAC
President of the Turkish Vaccine Institute and Member of the Scientific Council on Coronavirus Prof. Doctor:
The initial data are very positive. Among the who underwent TURKOVAC, there was no one who had severe COVID-19. The domestic vaccine also rapidly raised antibody levels. It can also be easily used as a third-dose vaccine
President of the Turkish Vaccination Institute and Member of the Scientific Committee on Coronavirus of the Ministry of Health Prof. Dr. evaluated the preliminary results obtained in clinical trials conducted on the domestic inactive COVID-19 vaccine TURKOVAC. To note that the data of the TURKOVAC vaccine in clinical trials were quite positive, and positive results were also obtained from comparative data conducted with the inactive vaccine Sinovac.
Black, TURKOVAC applied between persons covid – 19 heavy-pass rapidly raise antibody levels should also receive the vaccine when Native saying, “This is the effectiveness of the vaccine, showing an advantage in terms of retention. At this point, our initial data are very positive. All of these data were submitted to the commissions evaluating the emergency use approval in detail. He is being evaluated very carefully.
During the production process, “stability” tests were performed to determine whether the amount of antigen in the vaccine was sufficient for the body and the expiration date. If TURKOVAC receives approval, it may be written on it that “It has a 3-month use period”. According to the results of stability tests, it can increase to 6 months. As a result of tests that will last for several years, the duration of use can also be determined as 1 or 2 years.
If the production, undesirable effects, and effectiveness are evaluated as ‘appropriate’ in the examinations conducted, mRNA can be made if desired in our country right now, inactive Sinovac vaccine can be made if desired, and TURKOVAC can also be easily used as a third vaccine. Anyone who wants to can also choose TURKOVAC as a vaccine dose,” he said.
.
.
.
.